Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction

Coronary Artery Disease

Volumn 17, Issue 5, 2006, Pages 431-437

  El Menyar, Ayman A ^a   Altamimi, Omar M ^a   Gomaa, Mohamed M ^a   Dabdoob, Wafer ^a   Abbas, Ali A ^a   Abdel Rahman, Mohammed O ^a   Bener, Abdulbari ^a   Albinali, Hajar A ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

Angiotensin converting enzyme; Metalyze; Myocardial infarction; Plasminogen activator inhibitor 1; Reteplase; Streptokinase

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOLYTIC AGENT; METALYZE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETEPLASE; STREPTOKINASE; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; ADULT; ARTICLE; BIOCHEMISTRY; BLOOD CLOT LYSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PLASMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE DISEASE; DECISION MAKING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECOMBINANT PROTEINS; STREPTOKINASE; STROKE VOLUME; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33748190668     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200608000-00006     Document Type: Article

References (39)

1. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
2. Jansonn JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation 1993; 88:2030-2034.
3. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. pp. 575-614.
4. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (tPA) and tPA/ PAI-1 complex in plasma. Blood 1990; 76:930-937.
5. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108:391-394.
6. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. N Engl J Med 1988; 77:1213-1220.
7. Smitherman TC. Considerations affecting selection of thrombolytic agents. Mol Biol Med 1991; 8:207-218.
8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-322.
9. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review.Drugs 1992; 44:293-325.
10. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85:305-312.
11. Gray RP, Yudkin YS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993; 70:530-536.
12. Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, Binder BR. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Z Kardiol 1993; 82:195-200.
13. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44:671-719.
14. Sarkar R, Misra A, Saxena R, Pandy R, Chaudhary D. Plasminogen activator inhibitor-1 activity in normoglycemic hypertriglyceridemic north Asian Indian subject. Indian Heart J 2001; 53:61-65.
15. Norusis MJ. SPSS/PC+ for Windows. Base system and advanced statistic user's guide, Windows version 11. Chicago, Illinois: SPSS Inc.; 1998.
16. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829-1839.
17. The GUSTO Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-1622.
18. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739-1746.
19. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108:2851-2856.
20. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990; 16:239-243.
21. Blackwell N, Hollins A, Gilmore G, Norton R. Antistreptokinase antibodies: implications for thrombolysis in a region with endemic streptococcal infection. J Clin Pathol 2005; 58:1005-1007.
22. Sinkovic A. Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction. Clin Cardiol 2000; 23:486-489.
23. Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J. In vitro simulation of therapeutic plasmatic fibrinolysis. Clin Appl Thromb Hemost 2003; 9:211-220.
24. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91:3670-3674.
25. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283-1294.
26. French JK, Andrews J, Manda SO, Stewart RA, McTigue JJ, White HD. Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction. Am Heart J 2002; 143:265-271.
27. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Am J Cardiol 2000; 85:299-304.
28. Buszman P, Szafranek A, Kalarus Z, Gasior M. Use of changes in ST segment elevation for prediction of infarct artery recanalization in acute myocardial infarction. Eur Heart J 1995; 16:1207-1214.
29. Stewart JT, French JK, Theroux P, Ramanathan K, Solymoss BC, Johnson R, White HD. Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1998; 31:1499-1505.
30. Lavin F, Kane M, Forde A, Ganon F, Daly K. Comparison of five cardiac markers in the detection of reperfusion after thrombolysis in acute myocardial infarction. Br Heart J 1995; 73:422-427.
31. Norris RM, Johnson RN, White HD, Robinson DR. Noninvasive diagnosis of infarct artery patency after acute myocardial infarction by use of serial plasma troponin T concentrations: importance of measurement of peak levels. Heart 1996; 75:481-485.
32. Matetzky S, Freimark D, Chouraqui P, Novikov I, Agranat O, Rabinowitz B, et al. The distinction between coronary and myocardial reperfusion after thrombolytic therapy by clinical markers of reperfusion. J Am Coll Cardiol 1998; 32:1326-1330.
33. Califf RM, O'Neil W, Stack RS, Aronson L, Mark DB, Mantell S, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988; 108:658-662.
34. Becker RC. Reocclusion following successful thrombolysis. Emerging concepts. Cardiology 1993; 82:265-273.
35. Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991; 18:1547-1557.
36. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis arteriosclerosis. Thromb Vasc Biol 2003; 23:1979-1989.
37. Erdos EG. Angiotensin I-converting enzyme and the changes in our concepts through the years. Hypertension 1990; 16:363-370.
38. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994; 90:669-676.
39. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism at the angiotensin-converting enzyme gene is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.